ClinicalTrials.gg
RecruitingNCT07053436Updated Oct 2, 2026

Horizon Two: HR NDMM (MMRC-100)

A Phase 2 interventional study of Bispecific Monoclonal Antibody and Triplet Therapy and Monoclonal Antibody with Stem Cell Transplant in High Risk Newly Diagnosed Multiple Myeloma, sponsored by Multiple Myeloma Research Consortium. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Multiple Myeloma Research Consortium · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 2, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Planned enrollment
5th of 16
300 · median 168
Started
2026
with 6 others
Phase 2
5 of 16
4 open now
Primary completion
2035-10
later than 12 of 14 live
Registered
10th of 16
by date
Lead sponsor
1 of 16
Multiple Myeloma Research Consortium

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 5th largest by planned enrollment, is one of 7 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 12 of the 14 other live ones, and was the 10th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

Read the detailed description

The master protocol has broad scope and substantial flexibility, allowing each investigational arm within the platform to have its own design. The master protocol specifies general principles but the analysis plan for each investigational arm will be specified in its appendix. Details outlined in each investigational arm's appendix will include any co-primary endpoints (if applicable), the comparator arm, sample size and justification, inclusion of a safety run-in (if required), and any potential adaptations within the appendix. Accrual to an investigational arm will terminate in accord with its appendix.

As an adaptive platform trial, MMRC Horizon Two will evaluate multiple investigational arms against common controls. It is expected that the common controls may vary over time as standard of care therapy evolves. An initial common control arm will be specified in the control arm appendix. Changes in the common controls will be made through amendments to this appendix.

All patients will be randomized to an arm in the study. The default for the platform will be equal randomization to all arms that a patient is eligible. However, when there are more than two investigational arms and response adaptive randomization is deemed beneficial, it may be implemented in the trial.

Participants will be on study for 5 years from the date of randomization, inclusive of treatment and follow-up periods. Specifics on treatment duration and duration of follow up will be included in the respective arm appendix.

03

Conditions studied

  • High Risk Newly Diagnosed Multiple Myeloma

Browse trials for

Keywords

  • Horizon
  • Horizon Two
  • MMRC
  • HR NDMM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agree to participate by giving written

    -≥18 years of age

  • Symptomatic and transplant eligible newly diagnosed multiple myeloma confirmed per IMWG criteria that is high-risk as defined by at least one of the following:

    • Del(17p) (CCF ≥ 20%, by analyses conducted on CD138-positive/purified cells) and/or TP53 mutation assessed by NGS
    • One of these translocations-t(4;14) or t(14;16) or t(14;20)-co-occurring with +1q and/or del(1p32)
    • Monoallelic del(1p32) along with +1q, or biallelic del(1p32)
    • High β2M (≥5.5 mg/dL) with normal creatinine (\<1.2 mg/dL)
    • Presence of extra-medullary disease non-contiguous with bone at diagnosis (by PET-CT or Whole Body MRI)
    • Primary plasma cell leukemia (circulating plasma cells > 5% at diagnosis)
  • No more than 2 cycles of NCCN listed induction therapy for multiple myeloma
  • , per IMWG criteria, at time of diagnosis defined as one of the following:

    • Serum M-protein at diagnosis ≥ 0.5g/dL (0.3 g/dL or above if IgA subtype)
    • Urine M-protein ≥ 200 mg/24hours
    • Serum free light chain difference > 100 mg/L
    • Plasmacytoma ≥ 2cm
    • Bone marrow involvement ≥ 30%
  • performance status of 0-2
  • Adequate organ function, as indicated by the following laboratory values:

    • Adequate hematological function, defined as ≥ 1000/µL, count ≥ 75,000/µL, and ≥ 8 g/dL (transfusion and/or growth factor support is allowed for hematologic parameters as long as the investigator deems the patient otherwise fit for screening)
    • Adequate hepatic function, defined as total level ≤ 1.5 x institutional (IULN) except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤1.5 x IULN is required), ≤ 2.5 x IULN, and ALT ≤ 2.5 x IULN
    • Adequate renal function, defined as calculated ≥ 30 mL/min per institutional standard (assessment method should be recorded, measured or C-G acceptable)
  • Persons of must have a negative serum pregnancy test at screening (within 72 hours of first dose of trial medication). Non-childbearing potential for a person assigned as female at birth is defined as 1 of the following:

    --≥ 45 years of age and has not had menses for >1 year

    • Amenorrheic for > 2 years without a hysterectomy and/or oophorectomy and follicle-stimulating hormone value in the range upon pretrial (screening) evaluation
    • Status is post-hysterectomy, -oophorectomy, or -tubal ligation
  • Persons of childbearing potential must be willing to use highly effective measures during sexual contact with a person assigned as male at birth starting with the Screening visit through 90 days after last dose of trial medication.

    --Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.

  • Persons assigned as male at birth with a partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial starting with the Screening visit through 90 days after the last dose of trial medication is received. Persons assigned as male at birth with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

    --Note: Abstinence is acceptable if this is the established and preferred contraception method for the participant.

  • Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using Functional Classification. To be eligible for this trial, participants should be Class 2 or better. Class 2 is defined as slight limitation of physical activity, in which ordinary physical activity leads to fatigue, palpitation, or dyspnea; the person is comfortable at rest.
  • Prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of the arms are eligible for this trial.
  • Known infection and on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Evidence of chronic virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated.
  • History of virus (HCV) infection must have been treated and cured. For patients with known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Major concurrent illness or organ dysfunction including but not limited to the following:

    • POEMS syndrome
    • Symptomatic major organ involvement AL amyloidosis
  • History of allergy or known to any of the trial therapies or any of their , or to any of the trial therapies as outlined in the local prescribing information (e.g., United States Prescribing Information [USPI])
  • Complete spinal cord compression or CNS involvement
  • Known
  • Allogeneic tissue/solid organ transplant recipients with chronic requiring equivalent dose of > 20 mg prednisone
  • Active infection requiring treatment
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
  • Legally incapacitated or has limited legal capacity
  • Persons who are pregnant or breastfeeding
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Control Arm: Isa-KRd with Autologous Stem Cell Transplant

    Appendix A to the MMRC Horizon Two High Risk Newly Diagnosed Multiple Myeloma Master Protocol: Isa-KRd with Autologous Stem Cell Transplant in Patients with High Risk Newly Diagnosed Multiple Myeloma

    Drug: Monoclonal Antibody with Stem Cell Transplant

  • Experimental
    Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy

    Appendix B to the MMRC Horizon Two High Risk Newly Diagnosed Multiple Myeloma Master Protocol: Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy in Patients with High Risk Newly Diagnosed Multiple Myeloma

    Drug: Bispecific Monoclonal Antibody and Triplet Therapy

Interventions

  • DrugBispecific Monoclonal Antibody and Triplet Therapy

    Drug page: LinvoseltamabStudies of LinvoseltamabLinvoseltamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy

    Also known as: Linvoseltamab

  • DrugMonoclonal Antibody with Stem Cell Transplant

    Drug page: Antibodies, MonoclonalStudies of Antibodies, MonoclonalAntibodies, Monoclonal pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Isatuximab-KRd with Autologous Stem Cell Transplant

    Also known as: Isatuximab

06

What researchers measure

Primary outcomes

  1. Sustained measurable residual disease (MRD) negativity

    Sustained MRD negativity is defined as MRD negativity at a minimum threshold of one myeloma cell in one hundred thousand nucleated bone marrow cells at MRD assessments

    Time frame: 2 years post randomization

  2. Progression Free Survival

    PFS is defined as time from randomization to disease progression or death from any cause. Participants who have not progressed or died are censored at the date last known progression-free.

    Time frame: through study completion, roughly 5 years

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of people who have achieved a partial response (PR) or better according to the IMWG criteria within the defined period of time on trial.

    Time frame: 2 years

  2. Best overall response

    Best overall response (Stringent Complete Response \[sCR\], Complete Response \[CR\], Very Good Partial Response \[VGPR\], Partial Response \[PR\], Stable Disease \[SD\], Progressive Disease \[PD\]) by International Myeloma Working Group Response Criteria.

    Time frame: 2 years

  3. Two-year progression free survival rate

    Two-year progression free survival rate is defined as the proportion of participants alive and progression-free 24 months after randomization.

    Time frame: 24 months after randomization

  4. Overall survival (OS)

    OS is defined as the time from randomization to death. Alive participants are censored at the date last known alive.

    Time frame: through study completion, average of 5 years

  5. Duration of response (DoR)

    DoR is defined as time from the first observation of a confirmed response \[Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR)\] to first documentation of disease progression or death. Participants who have not progressed or died are censored at the date last known progression-free. The start date for DoR is the date the response was first observed, not the date of confirmation.

    Time frame: 2 years

  6. 12-month measurable residual disease (MRD) negativity

    12-month MRD negativity is defined as MRD negativity at a minimum threshold of one myeloma cell in one hundred thousand nucleated bone marrow cells at MRD assessment at disease restaging 1 (12 months±3 months from randomization). Measured using ClonoSEQ's standardized, commercial, next generation sequencing assay (preferred) or commercial multi-color flow cytometry.

    Time frame: 12 months from randomization

  7. Frequency and intensity of (serious) adverse events (S)AEs

    Assessed by NCI CTCAE version 5.0, including a focus on hematologic clinical laboratory abnormalities and changes.

    Time frame: through study completion, an average of 5 years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2035, 113 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 113 months is above that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jul 8, 2025
StartActual
Apr 30, 2026
Primary completionEst.
Oct 1, 2035
CompletionEst.
Oct 12, 2035
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 United States)
  • City of Hope · Duarte, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Mt. Sinai School of Medicine · New York, United States
  • Atrium Levine Cancer institute · Charlotte, United States
  • Tennessee Oncology · Nashville, United States
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    5 sites added
    Show 5 added (5 United States)
    • City of Hope · Duarte, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Mt. Sinai School of Medicine · New York, United States
    • Atrium Levine Cancer institute · Charlotte, United States
    • Tennessee Oncology · Nashville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07053436
Lead sponsor
Multiple Myeloma Research Consortium
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Apr 30, 2026
Primary completion
Oct 1, 2035 (estimated)
Completion
Oct 12, 2035 (estimated)
Last update
Oct 2, 2026

Study contacts

Jessica Vandermark
Contact
vandermarkj@themmrf.org
2036520457
Mercedes Martillo
Contact
martillom@themmrf.org
2036520457
Hearn Jay Cho, MD, PhD
principal investigator · Multiple Myeloma Research Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion